NeurologyLive® Friday 5 — November 3, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Thyroid-Stimulating Hormone Receptor in Duchenne Muscular Dystrophy

In this edition of NeuroPathways from our October Print, recent research has suggested a role for thyroid hormones and their receptor, thyrotropin, in muscle regeneration and development, making a case for further investigation in DMD.

2: The Role of Biomarkers in Myasthenia Gravis Diagnosis and Treatment: Hong Sun, MD, PhD

The senior director and global compound development team leader at Janssen talked about the importance of biomarkers in detecting an earlier diagnosis of myasthenia gravis and the significant unmet medical need for better treatment options. [WATCH TIME: 3 minutes]

3: NeuroVoices: David Greeley, MD, on AR1001, an Oral PDE5 Inhibitor for Alzheimer Disease

In this edition of NeuroVoices, David Greeley, MD, chief medical officer at AriBio and study author, provided commentary on the mechanism of action of AR1001, its promising effect on ptau181, and the next steps in its development.

4: Designing More Effective Proof-of-Concept Studies for Progressive MS Therapies: Robert J. Fox, MD

The vice-chair for research at Cleveland Clinic’s Neurological Institute discussed the way therapies are currently assessed for progressive MS and the need for disease-specific biomarkers. [WATCH TIME: 3 minutes]

5: Looking Ahead at MS Treatment and Closing Thoughts on Biosimilars

Jeffrey Cohen, MD; Sarah Anderson, PharmD, NBC-HWC; and Alicyn Magruder, PharmD, BCACP, MSCS, share their final thoughts on the future landscape of clinical MS care in the biosimiliars era. [WATCH TIME: 12 minutes]